- Home
- SEVN vs TNYA Comparison
SEVN vs TNYA Comparison
Compare SEVN & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- TNYA
- Stock Information
- Founded
- SEVN 1986
- TNYA 2016
- Country
- SEVN United States
- TNYA United States
- Employees
- SEVN N/A
- TNYA N/A
- Industry
- SEVN Real Estate Investment Trusts
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- SEVN Real Estate
- TNYA Health Care
- Exchange
- SEVN Nasdaq
- TNYA Nasdaq
- Market Cap
- SEVN 161.7M
- TNYA 189.1M
- IPO Year
- SEVN N/A
- TNYA 2021
- Fundamental
- Price
- SEVN $10.97
- TNYA $1.22
- Analyst Decision
- SEVN Strong Buy
- TNYA Strong Buy
- Analyst Count
- SEVN 2
- TNYA 5
- Target Price
- SEVN $13.50
- TNYA $8.60
- AVG Volume (30 Days)
- SEVN 38.1K
- TNYA 3.0M
- Earning Date
- SEVN 10-27-2025
- TNYA 11-05-2025
- Dividend Yield
- SEVN 10.06%
- TNYA N/A
- EPS Growth
- SEVN N/A
- TNYA N/A
- EPS
- SEVN 1.04
- TNYA N/A
- Revenue
- SEVN $29,272,000.00
- TNYA N/A
- Revenue This Year
- SEVN N/A
- TNYA N/A
- Revenue Next Year
- SEVN N/A
- TNYA N/A
- P/E Ratio
- SEVN $10.68
- TNYA N/A
- Revenue Growth
- SEVN N/A
- TNYA N/A
- 52 Week Low
- SEVN $10.01
- TNYA $0.36
- 52 Week High
- SEVN $14.66
- TNYA $4.01
- Technical
- Relative Strength Index (RSI)
- SEVN 54.65
- TNYA 56.83
- Support Level
- SEVN $10.75
- TNYA $1.15
- Resistance Level
- SEVN $11.04
- TNYA $1.43
- Average True Range (ATR)
- SEVN 0.18
- TNYA 0.10
- MACD
- SEVN 0.02
- TNYA -0.02
- Stochastic Oscillator
- SEVN 67.86
- TNYA 44.74
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.